Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
LivaNova heads into its October 28 earnings with short interest at a one-month high, a fresh bullish analyst initiation, and a stock that has given back nearly 9% over the past month.
The most immediate news is the analyst move. Barclays initiated coverage this week with an Overweight rating and a $105 target, a notable step given that the same firm's previous analyst carried an Equal-Weight with a $76 target as recently as May. The new target implies roughly 40% upside from Tuesday's close of $74.93. The broader Street remains constructive: Piper Sandler, Needham, Mizuho, and Keybanc have all raised targets in recent months, with the consensus sitting at a buy and the mean target near $90. One outlier, Freedom Capital Markets, initiated at Hold with an $81 target in July. The bull case centres on strong revenue growth toward the $940 to $955 million management guidance range and the potential of the aura6000 neuromodulation device. Bears point to margin pressure, the risk of FDA delays for the aura6000, and slowing growth in both the cardiovascular and neuromodulation divisions.
Short positioning tells a more cautious story than the bullish analyst tone suggests. Short interest has climbed roughly 19% over the past month to reach 10.2% of free float, a level ORTEX classifies as high, with the most recent weekly reading up another 2.4%. That month-long build coincides almost exactly with the stock's 8.5% decline, suggesting shorts have been adding into weakness rather than being caught offside. The borrow market, however, is not under pressure. Availability remains very loose at around 480% of short interest, meaning there are nearly five times as many shares available to lend as there are shares currently borrowed. Cost to borrow is just 0.53%, low by any measure, though it has crept up 13.5% over the past month in line with the rising short count. The ORTEX short score has drifted higher through September, reaching 62 this week from below 59 a month ago, still a moderate reading rather than an extreme one.
Options positioning is neutral. The put/call ratio of 0.48 sits fractionally above its 20-day average of 0.46, a z-score of just 0.35, and well within the year's range of 0.07 to 0.88. Options traders are not adding meaningful downside protection ahead of the print, which stands in contrast to the short-interest build.
The institutional picture is broadly stable. BlackRock holds 13.7% of shares and added roughly 426,000 shares in the quarter to September. Invesco added 455,000 shares in the same period. Hood River Capital Management, a smaller active manager, reported a large position build of nearly 1.9 million shares as of June 30, taking its stake to 4.7% of the company. No 13D activist is on the register. The insider picture is mildly negative in aggregate: the 90-day net from open-market transactions is roughly minus $800,000 in value, with two directors selling small amounts in September at prices around $78 to $81, levels the stock has since fallen through. None of the sales were under a 10b5-1 plan.
Earnings history adds context to the short build. The last quarterly print in early August produced an 11% single-day decline and the stock was still down 5% five days later. The prior event in late July saw a 1.3% drop and a 5% decline over the following week. That back-to-back pattern of post-earnings weakness is the kind of outcome that tends to encourage short sellers to hold positions into the next release, which arrives in three weeks.
With the Barclays initiation landing above most existing targets, the next question is whether the updated bull case is enough to shift sentiment before October 28, or whether the month-long short build and the stock's recent underperformance relative to peers like BAX (up 3.7% on the week) and DEMANT (up 3.2%) becomes the dominant framing into the print.
See the live data behind this article on ORTEX.
Open LIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.